Pediatr. praxi 2019; 20(4): 270-274

Functional digestive disorders, phytotherapy by preparation STW 5 (Iberogast®)

MUDr. Vít Navrátil
II. interní klinika – gastroenterologická a geriatrická, LF UP a FN Olomouc

Dyspepsia is one of the most common cause of visiting a pharmacy or a physician. It is a heterogenous group of unpleasant symptoms concerning the digestive tract, abdomen, intake of food and bowel movement. Subject of the first part of the article is a brief review of digestive disorders, especially functional disorders, and a brief classification of them. Moreover it contains a summary of treatment possibilities. STW 5 (Iberogast®) is a fixed herbal combination product, available as a over-the-counter medicine. It is an effective, safe and well tolerated medicine. The second part of the article concerns with composition and data summary about effectivity and safety of STW 5 (Iberogast®).

Keywords: dyspepsia, self‑medication,STW 5 (Iberogast®), clinical studies

Published: September 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Navrátil V. Functional digestive disorders, phytotherapy by preparation STW 5 (Iberogast®). Pediatr. praxi. 2019;20(4):270-274.
Download citation

References

  1. Over-the-Counter Medications: Use in General and Special Populations, Therapeutic Errors, Misuse, Storage and Disposal [online]. 2011. American College of Preventive Medicine [cit. 2019-06-111]. Dostupný na WWW: < https://c.ymcdn.com/sites/www.acpm.org/resource/resmgr/timetools-files/otcmedstimetool.pdf >
  2. Ehrmann J. Funkční dyspepsie. Medicína pro praxi 2013; 10(2): 50-53.
  3. Rejchrt S, et al. Prevalence a sociodemografická charakteristika dyspepsie v České republice. Hradec Králové: Nucleus 2005.
  4. Schmulson M. J., Drossman D. A. What Is New in Rome IV. J Neurogastroenterol Motil. 2017; 23(2): 151-163. Go to original source... Go to PubMed...
  5. Drossman D. A. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology 2016; 150: 1262-1279. Go to original source... Go to PubMed...
  6. Kotolová H. Nezávažné trávicí potíže a možnosti samoléčení. Prakt. lékáren. 2019; 15(1): 46-53. Go to original source...
  7. Tan VP. The low-FODMAP diet in the management of functional dyspepsia in East and Southeast Asia. J Gastroenterol Hepatol. 2017 Mar;32 Suppl 1: 46-52. Go to original source... Go to PubMed...
  8. Werlang ME., Palmer, WC., Lacy BE. (2019). Irritable Bowel Syndrome and Dietary Interventions. Gastroenterology & hepatology, 15(1), 16-26. Go to PubMed...
  9. Leiman DA, Riff BP, Morgan S, et al. Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis. Dis Esophagus. 2017; 30(5): 1-9. Go to original source... Go to PubMed...
  10. Falzon CC, Balabanova A. Phytotherapy: An Introduction to Herbal Medicine. Prim Care. 2017 Jun; 44(2): 217-227. Go to original source... Go to PubMed...
  11. Rösch W, Liebregts T, Gundermann KJ, et al. Phytotherapy for functional dyspepsia: A review of the clinical evidence for the herbal preparation STW 5. Phytomedicine 2006; 13: 114-121. Go to original source... Go to PubMed...
  12. Kroll U, Cordes C. Pharmaceutical prerequisites for a multi-target therapy. Phytomedicine 2006; 13: 12-19. Go to original source... Go to PubMed...
  13. Ammon HPT, Kelber O, Okpanyi SN. Spasmolytic and tonic effect of Iberogasts (STW 5) in intestinal smooth muscle. Phytomedicine 2006; 13: 67-74. Go to original source... Go to PubMed...
  14. Bonaterra GA, et al. Mechanisms of the anti-proliferative and anti-inflammatory effects of the herbal fixed combination STW 5 (Iberogast(R)) on colon adenocarcinoma (HT29) cell in vitro. Phytomedicine 20 (2013); 691-698. Go to original source... Go to PubMed...
  15. S. Michael, et al. Inhibition of inflammation-induced alterations in rat small intestine by the herbal preparations STW 5 and STW 6. Phytomedicine 16 (2009); 161-171. Go to original source... Go to PubMed...
  16. Von Arnim U, Peitz U, Vinson B. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol. 2007; 102: 1268-1275. Go to original source... Go to PubMed...
  17. Braden B, Caspary W, Börner N. Clinical effects of STW 5 (Iberogast) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis. Neurogastroenterol Motil., 2009; 21(6): 632-638. Go to original source... Go to PubMed...
  18. Rösch W, Vinson B, Sassin I. A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. Z Gastroenterol. 2002; 40(6): 401-408. Go to original source... Go to PubMed...
  19. Sassin I, Buchert D. Efficacy and tolerability of the herbal preparation Iberogast(R) in the therapy of functional dyspepsia. Phytomedicine. 2000; 7: 91-92. Go to PubMed...
  20. Klein-Galczinsky C, Sassin I. Anwendungsbeobachtung zur Wirksamkeit und Verträglichkeit von Iberogast(R) in der Therapie des Colon irritabile. Phytotherapie an der Schwelle zum neuen Jahrtausend 1999; 125 (Abstract P25).
  21. Ottillinger B., Storr M., Malfertheiner P., Allescher H. D. STW 5 (Iberogast(R))--a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr. 2013; 163(3-4): 65-72. Go to original source... Go to PubMed...
  22. Saller R, Pfister-Hotz G, Iten F, et al. Iberogast: a modern phytotherapeutic combined herbal drug for the treatment of functional disorders of the gastrointestinal tract (dyspepsia, irritable bowel syndrome)-from phytomedicine to ''evidence based phytotherapy''. A systematic review. Forsch. Komplementaermed. 2002; 9; 1-20.
  23. Navrátil V, Dvoran P, Ďurana V, et al. Je funkčná dyspepsia skutočne tak častá?. Vnitrni lekarstvi. 2018; 64: 903-910. Go to original source... Go to PubMed...




Pediatrics for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.